Researchers looked at muscle relaxants — including benzodiazepine agents diazepam and triazolam and non- benzodiazepine agent zopiclone — and found they did not reduce pain when taken for up to two weeks, but use was associated with drowsiness and dizziness. They also looked at neuromodulators — including oral nefopam, topical capsaicin and oromucosal cannabis — and found weak evidence to support pain reduction. Use was associated with nausea, sweating, dizziness, dry mouth, light headedness, local burning and irritation.
Related Articles on Pain Management:
Will You or Your Group Participate in an ACO Arrangement in the Future? 5 Pain Management Physician Responses
Bill Would Prohibit Cash Payments in Kentucky Pain Clinics
Dr. Robert Cochran: Opiates Can Treat Bipolar Disorder
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
